此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Longitudinal Natural History Protocol for PRKN- and PINK1-Linked PD

Longitudinal Natural History Protocol for PRKN- and PINK1-linked PD

Background:

Parkinson s disease is a neurologic disorder that affects movement. Its cause is unknown, and it usually begins later in life. Gene changes (PRKN and PINK1) can also cause rare types of Parkinson s disease that start at a young age. Researchers want to conduct a natural history study to learn more about how genes play a role in Parkinson s disease.

Objective:

To collect data and biological samples from people with different types of Parkinson s disease.

Eligibility:

People aged 18 to 80 years with either Parkinson s disease or PRKN- and PINK1-linked Parkinson s disease. Healthy volunteers are also needed.

Design:

Participants will have 6 clinic visits over 5 years. Each visit may take 1 to 3 days.

During each visit:

Participants will have a physical exam. The exam will be videotaped.

They will answer questions about their movement, thinking, mood, and sense of smell. The extent of any symptoms of Parkinson s disease will be evaluated: Participants movements may be assessed with a finger tapping test. They may be asked to scratch and sniff different scented strips to identify odors.

They will wear motion sensors on their arms, legs, chest, and back at the clinic. They will wear motion sensor devices on their wrists at home for 1 week.

Blood and urine samples will be collected.

Other tests are optional:

Magnetic resonance imaging (MRI) scan of the brain. Participants will lie on a table that slides into a tube.

Lumbar puncture (spinal tap). A thin needle will be inserted into their lower back to draw out a sample of the fluid around their spinal cord.

Muscle biopsy. A small sample of tissue will be taken from the leg.

研究概览

地位

尚未招聘

条件

详细说明

Study Description:

This is a longitudinal, observational study that aims to assess progression of clinical features, imaging, and biologic markers of PD in study participants with and without manifest PD who are bi-allelic or mono-allelic carriers of pathogenic variants in the recessively inherited genes PRKN and PINK1 that represent prototypes of mitochondrial- associated PD.

Objectives:

Primary Objective: To characterize the natural history of motor symptoms in PRKN- and PINK1-linked PD.

Secondary Objectives: To comprehensively characterize other clinical features of PRKN- and PINK1-linked PD over time

Tertiary Objectives:

  • To characterize structural brain changes over time
  • To identify molecular signatures that differ between PRKN and PINK1-associated PD, non-manifesting mutation carriers, wildtype PD, and healthy controls.
  • To generate a repository of longitudinal data and samples for future studies aimed at developing targeted therapies.
  • To characterize in-home assessment of movements
  • To evaluate for mitochondrial changes in the muscle

Endpoints:

Primary Endpoint: Annual change in MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III

Secondary Endpoints:

  • Annual change in MDS-UPDRS parts I, II, IV
  • Annual change in Montreal Cognitive Assessment (MoCA)
  • Annual change in Timed up and go (TUG)
  • Annual change in 10-meter walk
  • Annual change in 360 degree turn
  • Annual change in Unified Dyskinesia Rating Scale (UDysRS)
  • Annual change in University of Pennsylvania Smell Identification Test (UPSIT)
  • Annual change in REM-Sleep-Behavior Disorder Screening Questionnaire (RBD-SQ)
  • Annual change in Questionnaire for Impulsive-Compulsive Disorders (QUIP)
  • Annual change in Epworth Sleepiness Scale (ESS)
  • Annual change in Geriatric Depression Scale (GDS)
  • Annual change in State-Trait Anxiety Inventory (STAI)
  • Annual change in Scales for Outcomes in Parkinson s Disease - Autonomic Dysfunction (SCOPA AUT)
  • Annual change in 39-item Parkinson s Disease Questionnaire (PDQ-39)- quality of life measurement
  • Annual change in Schwab and England Activities of Daily Living (SE-ADL) scale
  • Annual change in Hoehn and Yahr scale assessment Tertiary endpoints:
  • Annual change of brain MRI measurement of overall brain, striatum and substantia nigra volumes
  • Annual change of brain MRI measurement of iron deposition
  • Annual change in studies from blood
  • Annual change in studies from CSF
  • Annual change in studies from urine
  • Annual change in Wearable Accelerometry data
  • Evidence of mitochondrial cytopathy on muscle biopsy

研究类型

观察性的

注册 (估计的)

70

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Maryland
      • Bethesda、Maryland、美国、20892
        • National Institutes of Health Clinical Center
        • 接触:
          • NIH Clinical Center Office of Patient Recruitment (OPR)
          • 电话号码:TTY dial 711 800-411-1222
          • 邮箱ccopr@nih.gov

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

取样方法

非概率样本

研究人群

There will be a total of up to 50 male or female participants 18- 80 years of age and older in 5 cohorts. Target number of completers for each cohort are listed below: - PD mito-biallelic (PD participants carrying two pathogenic variants in PRKN or PINK1): up to 15 - PD mito-monoallelic (PD participants carrying one pathogenic mono-allelic variant in PRKN and/or PINK1): up to 10 - PD idiopathic: up to 5 - Non-manifesting mito (participants who carry one or two pathogenic variants in PRKN and/or PINK1 but do not have a diagnosis of PD): up to 15 - Healthy controls: up to 5

描述

  • INCLUSION CRITERIA:

To be eligible to participate in this study, an individual must meet all of the following criteria:

All participants:

  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female between the ages of 18-80 years old
  • Ability of subject to understand and the willingness to sign an informed consent document
  • Ability of subject to travel to the NIH Clinical Center

Additional inclusion criteria for each cohort as below:

PD Mito - Biallelic:

  • Established clinical diagnosis of Parkinson's disease
  • Two Pathogenic or likely pathogenic variants in PRKN or PINK1

PD Mito - Monoallelic:

  • Established clinical diagnosis of Parkinson's disease
  • One Pathogenic or likely pathogenic variant in PRKN and/or PINK1

Idiopathic Parkinson's Disease (PD):

  • Established clinical diagnosis of Parkinson's disease
  • Etiology of PD is idiopathic/sporadic based on investigator determination

Non-manifesting mito:

  • One or two pathogenic or likely pathogenic variant in PRKN and/or PINK1
  • Lack of clinical diagnosis of Parkinson's disease
  • Lack of current or clinically significant neurological disorder (based on investigator determination)

Healthy Volunteer

-Lack of current or clinically significant neurological disorder (based on investigator determination)

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

All participants:

  • Symptomatic PD syndromes due to drugs (e.g., metoclopramide, flunarizine, neuroleptics), metabolic disorders (e.g., Wilson's disease hypothyroidism), encephalitis, brain lesion, atypical parkinsonism, other monogenic forms of PD (e.g., GBA1, LRRK2, SNCA, VPS35, CHCHD2, DJ1, ATP13A2) other genetic disorders that may cause parkinsonism (e.g., spinocerebellar ataxia, X-linked dystonia parkinsonism)
  • Pregnancy at time of study enrollment
  • Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment
  • Unwilling to allow samples or data to be shared with other researchers or institutions.
  • NIH staff or family members of study team members

Healthy Volunteer:

-Participants who become pregnant during the study will be withdrawn from further study procedures at the time pregnancy is identified.

Procedural Exclusions:

Subjects may still be enrolled if they cannot participate in certain procedures due to not meeting the inclusion requirements for that specific procedure. Subjects who meet exclusion criteria for procedures listed below may still undergo the procedure at a later time if the reason of exclusion is no longer present.

Brain MRI:

  • Contraindications to MRI such as a contraindicated non-removable metal device (i.e., pacemaker, defibrillator, insulin pump, metal clips, non-removable jewelry)
  • Pregnancy

Accelerometer:

-Non ambulatory

Lumbar puncture procedure:

  • PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants)
  • INR greater than 1.4, thrombocytopenia (<70,000), or abnormal bleeding time or platelet dysfunction
  • History of a bleeding disorder
  • Use of anticoagulants or antiplatelets
  • Pregnancy
  • History of headache requiring blood patch after a previous LP

Needle muscle biopsy:

  • PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants)
  • INR greater than 1.4, thrombocytopenia (<70,000), or abnormal bleeding time or platelet dysfunction
  • History of a bleeding disorder
  • Use of anticoagulants or antiplatelets
  • Pregnancy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Healthy controls
Lack of current or clinically significant neurological disorder (based on investigator determination).
Non-manifesting mito
participants who carry one or two pathogenic variants in PRKN and/or PINK1 but do not have a diagnosis of PD
PD idiopathic
PD participants with idiopathic PD
PD mito - monoallelic
Monoallelic: PD participants carrying one pathogenic mono-allelic variant in PRKN and/or PINK1
PD mito - biallelic
Biallelic: PD participants carrying two pathogenic variants in PRKN or PINK1

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Estimation of progression of motor symptoms across cohorts
大体时间:When final patient completes their last visit
Measured by annual change in MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
When final patient completes their last visit

次要结果测量

结果测量
措施说明
大体时间
Annual change in MDS-UPDRS parts I, II, IV
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Montreal Cognitive Assessment (MoCA)
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Timed up and go (TUG)
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in 10-meter walk
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in 360 degree turn
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Unified Dyskinesia Rating Scale (UDysRS)
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in University of Pennsylvania Smell Identification Test (UPSIT)
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in REM-Sleep-Behavior Disorder Screening Questionnaire (RBD-SQ)
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Questionnaire for Impulsive-Compulsive Disorders (QUIP)
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Epworth Sleepiness Scale (ESS)
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Geriatric Depression Scale (GDS)
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in State-Trait Anxiety Inventory (STAI)
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA AUT)
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in 39-item Parkinson's Disease Questionnaire (PDQ-39) - quality of life measurement
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Schwab and England Activities of Daily Living (SE-ADL) scale
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Hoehn and Yahr scale assessment
大体时间:When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Debra J Ehrlich, M.D.、National Institute of Neurological Disorders and Stroke (NINDS)

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2036年5月30日

研究完成 (估计的)

2036年5月30日

研究注册日期

首次提交

2026年5月28日

首先提交符合 QC 标准的

2026年5月28日

首次发布 (实际的)

2026年5月29日

研究记录更新

最后更新发布 (实际的)

2026年6月18日

上次提交的符合 QC 标准的更新

2026年6月17日

最后验证

2026年6月16日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • 10002619
  • 002619-N

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅